Graft fibrosis after pediatric liver transplantation: ten years of follow-up

Hepatology. 2009 Mar;49(3):880-6. doi: 10.1002/hep.22686.

Abstract

Previously we reported the presence of portal fibrosis in 31% (n = 84) of the grafts in protocol biopsies 1 year after pediatric liver transplantation (LTx). To assess the natural history of graft fibrosis after pediatric liver transplantation, we extended the analysis of graft histology in follow-up protocol biopsy specimens obtained 5 and 10 years after transplantation. We correlated histological results with clinical parameters at the time of LTx and during follow-up, to allow identification of risk factors for the development of fibrosis. From 1 year to 5 years after LTx, the prevalence of fibrosis increased from 31% to 65% (n = 66) but remained stable thereafter (at 10 years, 69%, n = 55). At 10 years after LTx, however, the percentage of patients with severe fibrosis had increased from 10% (at 5 years) to 29%. Of the 69% of children without fibrosis at 1 year post-transplantation, 64% (n = 39) had developed some degree of fibrosis at 10 years. Fibrosis was strongly related to transplant-related factors such as prolonged cold ischemia time, young age at the time of transplantation, high donor/recipient age ratio, and the use of partial grafts (P < 0.05). Fibrosis was not significantly related to rejection, chronic hepatitis, or the nature of the immunosuppressive therapy.

Conclusion: Biopsies after pediatric LTx show that most grafts developed fibrosis within 5 years. At 10 years after LTx, the graft fibrosis had progressed to severe fibrosis in at least 25% of the patients. Development of fibrosis, starting either before or after the first year post-LTx, was strongly related to transplant-related factors, indicating the importance of these factors to long-term graft prognosis.

MeSH terms

  • Adolescent
  • Age Factors
  • Alanine Transaminase / metabolism
  • Aspartate Aminotransferases / metabolism
  • Biopsy
  • Child
  • Child, Preschool
  • Cold Ischemia
  • Disease Progression*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppression Therapy
  • Infant
  • Liver / enzymology
  • Liver / pathology*
  • Liver Cirrhosis / epidemiology*
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / pathology*
  • Liver Function Tests
  • Liver Transplantation / immunology
  • Liver Transplantation / pathology*
  • Longitudinal Studies
  • Male
  • Risk Factors
  • Transplantation Tolerance / immunology

Substances

  • Aspartate Aminotransferases
  • Alanine Transaminase